Literature DB >> 19321621

Kaposi's sarcoma-associated herpesvirus K-bZIP protein is necessary for lytic viral gene expression, DNA replication, and virion production in primary effusion lymphoma cell lines.

Sylvain Lefort1, Louis Flamand.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of three human proliferative disorders, namely, Kaposi's sarcoma, primary effusion lymphomas (PEL), and multicentric Castleman's disease. Lytic DNA replication of KSHV, which is essential for viral propagation, requires the binding of at least two KSHV proteins, replication and transactivation activator (RTA) and K-bZIP, on the lytic origin of replication. Moreover, K-bZIP physically interacts with RTA and represses its transactivation activity on several viral promoters in transient transfection assays. To evaluate the physiological roles of K-bZIP in the context of PEL, we generated BCBL-1 cells with a tetracycline (Tet)-inducible small hairpin RNA (shRNA) directed against the K8 mRNA to knock down K-bZIP expression at different points during KSHV's life cycle. Using this model, we demonstrate that in the absence of K-bZIP expression, dramatic decreases in orf50, orf57, and orf26 transcript expression are observed. Similar effects were seen at the protein level for RTA (immediate-early protein) and K8.1 (late protein) expression. Interestingly, a direct correlation between K-bZIP levels and viral lytic mRNAs was noticed. As a consequence of K-bZIP knockdown, viral DNA replication and virion production were severely impaired. The same effects were observed following knockdown of K-bZIP in another PEL cell line, BC3. Finally, using shRNA-K8-inducible 293 cells, we report that de novo synthesis of K-bZIP is not necessary for initiation of infection and latency establishment. These data support the concept that K-bZIP is essential for lytic viral gene expression, viral DNA replication, and virus propagation in PEL cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321621      PMCID: PMC2681977          DOI: 10.1128/JVI.01821-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  A replication function associated with the activation domain of the Epstein-Barr virus Zta transactivator.

Authors:  R T Sarisky; Z Gao; P M Lieberman; E D Fixman; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

2.  Replication of Epstein-Barr virus oriLyt: lack of a dedicated virally encoded origin-binding protein and dependence on Zta in cotransfection assays.

Authors:  E D Fixman; G S Hayward; S D Hayward
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

3.  Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.

Authors:  G Miller; L Heston; E Grogan; L Gradoville; M Rigsby; R Sun; D Shedd; V M Kushnaryov; S Grossberg; Y Chang
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus.

Authors:  R Sun; S F Lin; L Gradoville; Y Yuan; F Zhu; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

5.  Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression.

Authors:  R Sun; S F Lin; K Staskus; L Gradoville; E Grogan; A Haase; G Miller
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus encodes a bZIP protein with homology to BZLF1 of Epstein-Barr virus.

Authors:  S F Lin; D R Robinson; G Miller; H J Kung
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.

Authors:  L Arvanitakis; E A Mesri; R G Nador; J W Said; A S Asch; D M Knowles; E Cesarman
Journal:  Blood       Date:  1996-10-01       Impact factor: 22.113

8.  Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection.

Authors:  G Miller; M O Rigsby; L Heston; E Grogan; R Sun; C Metroka; J A Levy; S J Gao; Y Chang; P Moore
Journal:  N Engl J Med       Date:  1996-05-16       Impact factor: 91.245

9.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.

Authors:  J Soulier; L Grollet; E Oksenhendler; P Cacoub; D Cazals-Hatem; P Babinet; M F d'Agay; J P Clauvel; M Raphael; L Degos
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113

10.  Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.

Authors:  R Renne; W Zhong; B Herndier; M McGrath; N Abbey; D Kedes; D Ganem
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  21 in total

1.  Histone demethylase JMJD2A regulates Kaposi's sarcoma-associated herpesvirus replication and is targeted by a viral transcriptional factor.

Authors:  Pei-Ching Chang; Latricia D Fitzgerald; Datsun A Hsia; Yoshihiro Izumiya; Chun-Yi Wu; Wen-Ping Hsieh; Su-Fang Lin; Mel Campbell; Kit S Lam; Paul A Luciw; Clifford G Tepper; Hsing-Jien Kung
Journal:  J Virol       Date:  2011-01-12       Impact factor: 5.103

Review 2.  Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis.

Authors:  Denis Avey; Brittany Brewers; Fanxiu Zhu
Journal:  Virol Sin       Date:  2015-04-23       Impact factor: 4.327

3.  Initiation of lytic DNA replication in Epstein-Barr virus: search for a common family mechanism.

Authors:  Andrew J Rennekamp; Paul M Lieberman
Journal:  Future Virol       Date:  2010-01       Impact factor: 1.831

4.  Leucine zipper domain is required for Kaposi sarcoma-associated herpesvirus (KSHV) K-bZIP protein to interact with histone deacetylase and is important for KSHV replication.

Authors:  Francisco Puerta Martínez; Qiyi Tang
Journal:  J Biol Chem       Date:  2012-03-13       Impact factor: 5.157

5.  Inhibition of Kaposi's sarcoma-associated herpesvirus lytic replication by HIV-1 Nef and cellular microRNA hsa-miR-1258.

Authors:  Qin Yan; Xinting Ma; Chenyou Shen; Xu Cao; Ninghan Feng; Di Qin; Yi Zeng; Jianzhong Zhu; Shou-Jiang Gao; Chun Lu
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

6.  Tracking expression and subcellular localization of RNA and protein species using high-throughput single cell imaging flow cytometry.

Authors:  Sumit Borah; Lisa A Nichols; Lynn M Hassman; Dean H Kedes; Joan A Steitz
Journal:  RNA       Date:  2012-06-28       Impact factor: 4.942

7.  Chromatin immunoprecipitation and microarray analysis suggest functional cooperation between Kaposi's Sarcoma-associated herpesvirus ORF57 and K-bZIP.

Authors:  Olga V Hunter; Emi Sei; R Blake Richardson; Nicholas K Conrad
Journal:  J Virol       Date:  2013-01-30       Impact factor: 5.103

8.  Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen inhibits interferon (IFN) beta expression by competing with IFN regulatory factor-3 for binding to IFNB promoter.

Authors:  Nathalie Cloutier; Louis Flamand
Journal:  J Biol Chem       Date:  2010-01-04       Impact factor: 5.157

9.  Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.

Authors:  Shruti Bhatt; Brittany M Ashlock; Ngoc L Toomey; Luis A Diaz; Enrique A Mesri; Izidore S Lossos; Juan Carlos Ramos
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

10.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 K-bZIP modulates latency-associated nuclear protein-mediated suppression of lytic origin-dependent DNA synthesis.

Authors:  Cyprian Rossetto; Irena Yamboliev; Gregory S Pari
Journal:  J Virol       Date:  2009-06-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.